Cutaneous T Cell Lymphoma News and Research

RSS

Psoriasis patients still need long-established treatment alternatives

For patients with severe psoriasis, a new class of intravenous and injectable biological medicines known as "biologics" has brought about a near revolution in treatment.

21 Apr 2011

FOLOTYN Phase 2 peripheral T-cell lymphoma study results published in Journal of Clinical Oncology

Allos Therapeutics, Inc. today announced that the Journal of Clinical Oncology has published data from the Company's pivotal Phase 2 PROPEL study demonstrating clinical activity of FOLOTYN® (pralatrexate injection) in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).

20 Jan 2011

$Updated Phase 1 study results of FOLOTYN in patients with refractory CTCL presented at ASH 2010$

Updated Phase 1 study results of FOLOTYN in patients with refractory CTCL presented at ASH 2010

Allos Therapeutics, Inc. today reported updated results from the Company's Phase 1 dose-finding study of FOLOTYN® (pralatrexate injection) which supports the selection of 15 mg/m2 weekly for three weeks out of a four-week cycle as the optimal starting dose and schedule for further evaluation in patients with relapsed or refractory cutaneous T-cell lymphoma. Data were presented at the 52nd American Society of Hematology Annual Meeting in Orlando, Florida.

6 Dec 2010

Elorac's naloxone lotion receives FDA Orphan Drug Designation for pruritus associated with mycosis fungoides

Elorac, Inc., a rapidly growing specialty pharmaceutical company focused on the treatment of dermatological disorders announced that it has been granted Orphan Drug Designation by the U.S. Food and Drug Administration for its naloxone lotion for the topical treatment of pruritus accompanying cutaneous t-cell lymphoma (CTCL, also known as mycosis fungoides).

1 Dec 2010

Allos Therapeutics to present FOLOTYN data for blood cancers at ASH Annual Meeting

Allos Therapeutics, Inc. today announced that five abstracts, describing FOLOTYN (pralatrexate injection) data across different types of blood cancers, were accepted in the program for this year's 52nd American Society of Hematology (ASH) Annual Meeting to be held December 4-7, 2010, in Orlando, Florida.

20 Nov 2010

Cyclacel announces publication of sapacitabine in British Journal of Cancer

Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious diseases, announced today publication of data demonstrating that its sapacitabine oral nucleoside analog works synergistically with histone deacetylase (HDAC) inhibitors to induce significant reductions in tumor cell growth in both in vitro and in vivo preclinical models.

11 Nov 2010

BioCryst 2010 third quarter revenue increases from $10.5 million to $12.0 million

BioCryst Pharmaceuticals, Inc. announced financial results for the third quarter and nine months ended September 30, 2010.

28 Oct 2010

EC grants orphan medicinal product designation to Allos' pralatrexate for Hodgkin lymphoma

Allos Therapeutics, Inc. announced today that the European Commission (EC) has granted orphan medicinal product designation for pralatrexate for the treatment of Hodgkin lymphoma (HL). The Company is currently investigating pralatrexate in a number of ongoing studies, including a Phase 2 clinical study in patients with relapsed or refractory non-Hodgkin lymphoma or Hodgkin lymphoma.

15 Oct 2010

Yaupon reports positive results from mechlorethamine gel study for early-stage cutaneous T-cell lymphoma

Yaupon Therapeutics, a privately held specialty pharmaceutical company, today announced positive top-line results from the pivotal multi-center study of its lead product candidate, a proprietary topical mechlorethamine gel for the treatment of early-stage cutaneous T-cell lymphoma (CTCL - stages I-IIa). The top-line data show that the study, which was conducted under a Special Protocol Assessment (SPA), achieved its primary and secondary endpoints.

24 Sep 2010

BioCryst reports results from forodesine studies for CTCL and CLL

BioCryst Pharmaceuticals, Inc. announced preliminary top-line results from its multinational, open-label, single-arm trial evaluating 200 mg once-daily oral forodesine in the treatment of relapsed or refractory cutaneous T-cell lymphoma (CTCL), as well as interim results from the Company's exploratory Phase 2 study to investigate the efficacy and safety of 200 mg twice-daily oral forodesine as monotherapy for chronic lymphocytic leukemia (CLL).

15 Sep 2010

TenX Biopharma recommences enrollment in suspended Phase III trial for cutaneous T-cell lymphoma

TenX Biopharma, Inc. announced today that it has re-initiated enrollment in the pivotal Phase III clinical trial assessing zanolimumab treatment for cutaneous T-cell lymphoma (CTCL) patients (ClinicalTrials.gov identifier: NCT00127881). The trial enrollment was suspended in October 2008 while Genmab was seeking a out-license agreement to further develop the compound. TenX Biopharma acquired global rights to zanolimumab in February, 2010 from Genmab.

7 Sep 2010

BioCryst second-quarter total revenues increase to $7.6 million

BioCryst Pharmaceuticals, Inc. announced financial results for the second quarter and six months ended June 30, 2010.

5 Aug 2010

Allos reports net loss of $20.0 million for second-quarter 2010

Allos Therapeutics, Inc. today reported its financial results and business highlights for the quarter and six months ended June 30, 2010.

28 Jul 2010

LLS collaborates with Shape Pharmaceuticals to advance treatment for CTCL

The Leukemia & Lymphoma Society (LLS) and Shape Pharmaceuticals announced today that they have entered into a partnership to advance Shape's novel, topical treatment for cutaneous T-Cell lymphoma (CTCL) into clinical development. The compound, SHP-141, is a first-in-class topical histone deacetylase inhibitor with the potential to treat both early- and late-stage CTCL.

28 Jul 2010

Investment report on BioCryst Pharmaceuticals

MicroStockProfit.com announces an investment report featuring BioCryst Pharmaceuticals Inc.. The report includes financial, comparative and investment analyses, and recent company news that you need to know to make an educated investment decision.

30 Jun 2010

EC grants Allos Therapeutics' pralatrexate orphan medicinal product designation for CTCL treatment

Allos Therapeutics, Inc. announced today that the European Commission (EC) has granted orphan medicinal product designation for pralatrexate for the treatment of cutaneous T-cell lymphoma (CTCL). The Company is currently investigating pralatrexate in a Phase 1 clinical study in patients with relapsed or refractory CTCL.

18 Jun 2010

$Data from Phase 1 study of FOLOTYN in patients with relapsed or refractory CTCL presented at EHA 2010$

Data from Phase 1 study of FOLOTYN in patients with relapsed or refractory CTCL presented at EHA 2010

Allos Therapeutics, Inc. today announced updated data from its ongoing dose finding Phase 1 study of FOLOTYN (pralatrexate injection) in patients with relapsed or refractory cutaneous T-cell lymphoma, a group of often slow-growing non-Hodgkins lymphomas that primarily manifest in the skin. These data were presented during a poster presentation at the European Hematology Association meeting being held June 10-13, 2010 in Barcelona, Spain.

11 Jun 2010

John Theurer Cancer Center to showcase treatment advancements for cancer at ASCO 2010

The John Theurer Cancer Center at Hackensack University Medical Center announced today important research findings that will be presented at the American Society of Clinical Oncology annual meeting taking place June 4 - 8, 2010 in Chicago. Research highlights include a comparison of first-line treatments for an aggressive form of lymphoma, the efficacy and safety of a new genetically engineered cancer therapy, and the value of a commonly used tool for staging lymphoma.

5 Jun 2010

Physicians and researchers to present 16 abstracts on cancer research at ASCO 2010

The John Theurer Cancer Center at Hackensack University Medical Center announced today that its physicians and researchers will present 16 abstracts on treatment and diagnostic progress in many different areas of oncology during the Annual Meeting of American Society of Clinical Oncology in Chicago, IL from June 4-8.

4 Jun 2010

Allos Therapeutics' FOLOTYN data to be presented at 46th ASCO and 15th EHA Congress

Allos Therapeutics, Inc. today announced that data on FOLOTYN® (pralatrexate injection) will be presented at two upcoming medical conferences: the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO), which will be held June 4-8 in Chicago, Illinois, and at the 15th Congress of the European Hematology Association (EHA), which will be held June 10-13 in Barcelona, Spain.

2 Jun 2010